Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - Deutsche Bank (ETR:DBKGn) raised its price target on Idorsia (SIX:IDIA) (OTC:IDRSF) stock to CHF2.00 from CHF1.00 while maintaining a Hold rating following the company’s Q2 2025 earnings results.
The Swiss pharmaceutical company reported strong beats versus Bloomberg consensus estimates for revenue and non-GAAP operating profit, which prompted management to improve guidance for the remainder of the year.
Idorsia’s management confirmed continued progress toward achieving overall profitability by 2027, though Deutsche Bank noted limited upside potential from both the company’s in-line and pipeline portfolio.
For Quviviq, Idorsia’s insomnia treatment, Deutsche Bank observed positive growth in European markets while U.S. sales remain stable, with future growth dependent on the potential descheduling of the DORA class of medications.
Regarding Tryvio, Deutsche Bank highlighted the lack of clarity on partnership timing, and while the removal of REMS from the U.S. label is positive, the bank believes the drug lacks clinical competitiveness due to mild efficacy and persistent safety concerns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.